GRANULOMATOSIS WITH POLYANGIITIS: CLINICAL FEATURES, INVESTIGATIONS, MANAGEMENT, PROGNOSIS, AND COMPLICATIONS

Granulomatosis with Polyangiitis (GPA), previously known as Wegener’s Granulomatosis, is a rare, severe, systemic autoimmune disease characterized by necrotizing granulomatous inflammation of the upper and lower respiratory tracts, small-vessel vasculitis, and typically glomerulonephritis. It is one of the Anti-Neutrophil Cytoplasmic Antibody (ANCA)-associated vasculitides (AAVs), predominantly associated with C-ANCA, which targets proteinase 3 (PR3). GPA can affect individuals of any age but most commonly presents in middle-aged adults, with a slight male predominance. Without timely diagnosis and aggressive treatment, GPA can be rapidly progressive and fatal.

Clinical Features

The clinical presentation of GPA is highly variable, ranging from localized disease to widespread, rapidly progressive multiorgan involvement. Symptoms often develop insidiously, making early diagnosis challenging. The classic triad involves upper respiratory tract, lower respiratory tract, and renal involvement, but other organ systems are frequently affected.

1. Upper Respiratory Tract (URT) Involvement: This is one of the most common and often initial sites of disease, affecting up to 90% of patients. Symptoms include chronic sinusitis (often recalcitrant to antibiotics), nasal crusting, purulent or bloody rhinorrhea, epistaxis, and nasal bridge collapse (saddle nose deformity) due to cartilage destruction. Otitis media, hearing loss, and subglottic stenosis (leading to hoarseness or stridor) are also common.
2. Lower Respiratory Tract (LRT) Involvement: Present in 50-80% of patients. Symptoms range from cough, dyspnea, hemoptysis, and pleuritic chest pain. Imaging often reveals pulmonary infiltrates, nodules (which may cavitate), or diffuse alveolar hemorrhage, often mimicking infection or malignancy.
3. Renal Involvement (Glomerulonephritis): Affects 70-80% of patients if untreated and is a major cause of morbidity and mortality. It typically presents as a rapidly progressive glomerulonephritis (RPGN) with microscopic hematuria, proteinuria, red blood cell casts, and progressive renal insufficiency. Early recognition is crucial to prevent irreversible renal failure requiring dialysis.
4. Systemic Symptoms: Nonspecific constitutional symptoms like fever, fatigue, malaise, anorexia, and weight loss are common and can precede organ-specific manifestations.
5. Musculoskeletal Involvement: Arthralgias and myalgias are frequent (up to 60%), often migratory and asymmetrical, primarily affecting large joints, but true arthritis is less common.
6. Cutaneous Manifestations: Occur in 40-50% of patients, including palpable purpura (due to leukocytoclastic vasculitis), ulcers, nodules, papules, and livedo reticularis.
7. Ocular Involvement: Present in 30-50% of cases, ranging from conjunctivitis, episcleritis, scleritis (often necrotizing), orbital pseudotumor (proptosis, diplopia, vision loss), and dacryocystitis.
8. Neurological Involvement: Peripheral neuropathy (mononeuritis multiplex or polyneuropathy) affects 15-20% of patients. Central nervous system involvement, though less common, can include cranial neuropathies, cerebral vasculitis leading to strokes, or pachymeningitis.
9. Gastrointestinal Involvement: Less common but can include abdominal pain, diarrhea, or hemorrhage due to vasculitis of mesenteric vessels.
10. Cardiac Involvement: Rare, but can include pericarditis, myocarditis, or coronary vasculitis.

Investigations

A high index of suspicion based on the clinical features is paramount for early diagnosis. Investigations aim to confirm the diagnosis, assess disease extent and severity, and rule out mimics.

1. Laboratory Tests:
   • ANCA Testing: The cornerstone of diagnosis. C-ANCA (anti-PR3) is found in 70-90% of patients with generalized GPA, while P-ANCA (anti-MPO) is less common (10-20%). While highly specific, ANCA can be negative, especially in localized disease. Titers may correlate with disease activity but are not universally reliable for monitoring.
   • Inflammatory Markers: Erythrocyte Sedimentation Rate (ESR) and C-Reactive Protein (CRP) are typically elevated and useful for monitoring disease activity.
   • Complete Blood Count (CBC): May show normocytic normochromic anemia (anemia of chronic disease) and leukocytosis. Eosinophilia is rare.
   • Renal Function Tests: Serum creatinine, blood urea nitrogen (BUN), and urinalysis are essential to detect glomerulonephritis. Urinalysis typically shows hematuria, proteinuria, and red blood cell casts.
   • Liver Function Tests: Generally normal, but may be mildly elevated in systemic disease.
   • Autoimmune Panel: ANA and RF are usually negative but may be done to exclude other autoimmune conditions.
2. Imaging Studies:
   • Chest X-ray/CT Scan: Crucial for assessing lung involvement. CT scans are more sensitive, revealing nodules (often cavitating), infiltrates, ground-glass opacities, or pleural effusions.
   • Sinus CT Scan: Demonstrates mucosal thickening, fluid accumulation, bone erosion, or soft tissue masses in the nasal passages and paranasal sinuses.
   • Renal Ultrasound: To assess kidney size and exclude obstructive uropathy, though often normal in GPA.
   • MRI/MRA: May be used for neurological involvement or to evaluate orbital pseudotumors.
3. Biopsy: This is the gold standard for definitive diagnosis, revealing the characteristic histopathological features.
   • Affected Organ Biopsy: The site depends on clinical presentation. Common sites include the lung, kidney, upper respiratory tract (nasal mucosa, sinus), or skin.
   • Histopathology: Shows necrotizing granulomatous inflammation, vasculitis (typically small- to medium-sized vessels), and necrosis. In the kidney, pauci-immune crescentic glomerulonephritis is classic.
   • Immunofluorescence: Typically negative or sparse for immunoglobulin and complement deposition (“pauci-immune”), distinguishing it from immune complex glomerulonephritis.

Management

The management of GPA requires a multidisciplinary approach involving rheumatologists, nephrologists, pulmonologists, otolaryngologists, ophthalmologists, and other specialists as needed. Treatment aims to induce remission, prevent relapses, and minimize treatment-related toxicity and permanent organ damage.

1. Induction of Remission: This phase is critical for controlling active disease and preventing irreversible organ damage.
   • Corticosteroids: High-dose systemic corticosteroids (e.g., methylprednisolone pulse therapy followed by oral prednisone) are the cornerstone of induction therapy for all forms of GPA.
   • Cyclophosphamide: For severe, generalized, or life-threatening disease (e.g., rapidly progressive glomerulonephritis, diffuse alveolar hemorrhage), oral or intravenous cyclophosphamide is the traditional first-line agent, typically for 3-6 months.
   • Rituximab: A B-cell depleting monoclonal antibody, rituximab is an equally effective alternative to cyclophosphamide for induction, particularly for non-life-threatening or relapsing disease, and is often preferred in patients where cyclophosphamide toxicity (e.g., infertility risk) is a concern. It has also shown superiority in preventing relapse compared to cyclophosphamide in some studies.
   • Plasma Exchange: May be considered in severe cases of rapidly progressive glomerulonephritis with pulmonary hemorrhage or very high creatinine levels, though its role in GPA (compared to goodpasture’s) is still debated.
2. Maintenance of Remission: Once remission is achieved, typically after 3-6 months, treatment transitions to less toxic immunosuppressants to prevent relapses. This phase usually lasts for at least 18-24 months, often longer.
   • Azathioprine: A common choice for maintenance, particularly after cyclophosphamide induction.
   • Methotrexate: Another option for maintenance, especially in patients with less severe disease or those intolerant to azathioprine.
   • Mycophenolate Mofetil (MMF): Can be used for maintenance, particularly if azathioprine or methotrexate are not tolerated or effective, though it may be less effective than azathioprine for relapse prevention.
   • Rituximab: Increasingly used for maintenance therapy, demonstrating superiority over azathioprine in preventing relapses in some studies, particularly in patients who achieved remission with rituximab or who have relapsing disease.
   • Corticosteroid Taper: Corticosteroids are gradually tapered to the lowest effective dose or discontinued if possible during the maintenance phase.
3. Adjunctive Therapies:
   • Pneumocystis Jirovecii Pneumonia (PJP) Prophylaxis: Co-trimoxazole (trimethoprim-sulfamethoxazole) is essential during induction and maintenance due to high-dose immunosuppression, and also has a small but recognized benefit in preventing GPA relapses, particularly in the upper respiratory tract.
   • Bone Protection: Calcium and vitamin D supplementation, and bisphosphonates if indicated, are crucial for patients on long-term corticosteroids.
   • Infection Prophylaxis: Vaccinations (influenza, pneumococcal) are recommended.
   • Management of Complications: Specific treatments for organ damage, such as dialysis for end-stage renal disease, or surgery for subglottic stenosis.

Prognosis

Before the advent of effective immunosuppressive therapies, GPA was almost uniformly fatal within months. With modern treatment, the prognosis has dramatically improved, with 5-year survival rates exceeding 80%. However, GPA remains a chronic, relapsing disease, and long-term morbidity is significant.

Factors influencing prognosis include:

• Disease Severity at Presentation: Patients with severe renal or pulmonary involvement tend to have a poorer prognosis.
• Response to Induction Therapy: Early and sustained remission is a positive prognostic indicator.
• Number and Severity of Relapses: Frequent or severe relapses contribute to cumulative organ damage and worse outcomes.
• ANCA Status: PR3-ANCA positive patients tend to have a higher risk of relapse compared to MPO-ANCA positive patients.
• Treatment-Related Complications: Infections and malignancy due to immunosuppression significantly impact long-term survival.

Despite improved survival, many patients experience chronic symptoms, treatment side effects, and permanent organ damage, impacting their quality of life. Regular monitoring for disease activity and treatment toxicity is essential.

Complications

Complications in GPA can arise directly from the disease process itself, leading to irreversible organ damage, or from the adverse effects of immunosuppressive therapies.

1. Disease-Related Complications:
   • End-Stage Renal Disease (ESRD): A major complication, requiring dialysis or kidney transplantation, occurring in 10-20% of patients with renal involvement despite treatment.
   • Chronic Respiratory Issues: Subglottic stenosis (requiring dilation or tracheostomy), chronic sinusitis, nasal septum perforation, and saddle nose deformity, significantly affecting quality of life. Pulmonary fibrosis is less common but can occur.
   • Ocular Damage: Permanent vision loss due to necrotzing scleritis, orbital pseudotumor, or optic nerve involvement.
   • Neurological Deficits: Persistent neuropathies, or rare but severe central nervous system damage.
   • Cardiovascular Disease: Increased risk of cardiovascular events, partly due to chronic inflammation and steroid use.
   • Chronic Pain and Fatigue: Common and often debilitating, impacting daily activities.
2. Treatment-Related Complications:
   • Infections: Significant risk, especially during induction therapy with cyclophosphamide and high-dose corticosteroids. Opportunistic infections (e.g., PJP, cytomegalovirus, fungal infections) are a major concern.
   • Malignancy: Long-term use of cyclophosphamide increases the risk of bladder cancer and lymphoid malignancies. Other immunosuppressants also carry a general increased risk of various cancers.
   • Bone Health: Osteoporosis and avascular necrosis due to prolonged corticosteroid use.
   • Infertility: Cyclophosphamide is gonadotoxic, particularly in women, leading to premature ovarian failure and infertility.
   • Cardiovascular Effects: Hypertension, hyperlipidemia, and diabetes mellitus are common side effects of corticosteroids, contributing to cardiovascular risk.
   • Hemorrhagic Cystitis: A rare complication of cyclophosphamide.
   • Leukopenia and Thrombocytopenia: Common side effects requiring dose adjustments for many immunosuppressants.

In conclusion, Granulomatosis with Polyangiitis is a challenging systemic vasculitis requiring prompt diagnosis and aggressive, multifaceted management. While the prognosis has vastly improved, the disease remains complex, necessitating individualized treatment strategies, diligent monitoring for both disease activity and treatment complications, and ongoing patient education and support to optimize long-term outcomes.

References

1. Jennette, J. C., & Falk, R. J. (2014). ANCA-associated vasculitis. New England Journal of Medicine, 371(16), 1538-1548.
2. Stone, J. H., Merkel, P. A., Spiera, R., Seo, P., Langford, C. A., Hoffman, G. S., … & Clinical Vasculitis Study Group. (2010). Rituximab versus cyclophosphamide for ANCA-associated vasculitis. New England Journal of Medicine, 363(3), 221-232.
3. Pagnoux, C., Mahr, A., Hamidou, M., Boffa, J. J., Heudier, P., Lesaulnier, F., … & French Vasculitis Study Group. (2008). Azathioprine or methotrexate maintenance for ANCA-associated vasculitis. New England Journal of Medicine, 359(26), 2790-2803.
4. Lally, L., & Spiera, R. F. (2015). Granulomatosis with Polyangiitis (Wegener’s). Rheumatic Disease Clinics of North America, 41(1), 1-18.
5. Falk, R. J., Jennette, J. C., Nachman, P. H., & Poulton, C. J. (2020). Chapel Hill Consensus Conference Nomenclature of Vasculitis. Arthritis & Rheumatology, 72(8), 1261-1270.
6. Mukhtyar, C., Guillevin, L., Cid, M. C., Dasgupta, B., de Groot, K., Gross, W., … & EULAR and ACR Recommendations. (2009). EULAR recommendations for the management of primary small and medium vessel vasculitis. Annals of the Rheumatic Diseases, 68(3), 310-317.
7. Rhee, R. L., & Chung, S. A. (2020). Updates on the Clinical Management of Granulomatosis with Polyangiitis. Current Rheumatology Reports, 22(12), 77.